<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id>
<journal-id journal-id-type="iso-abbrev">Proc. Natl. Acad. Sci. U.S.A</journal-id>
<journal-id journal-id-type="hwp">pnas</journal-id>
<journal-id journal-id-type="pmc">pnas</journal-id>
<journal-id journal-id-type="publisher-id">PNAS</journal-id>
<journal-title-group>
<journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title>
</journal-title-group>
<issn pub-type="ppub">0027-8424</issn>
<issn pub-type="epub">1091-6490</issn>
<publisher>
<publisher-name>National Academy of Sciences</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28348241</article-id>
<article-id pub-id-type="pmc">5402415</article-id>
<article-id pub-id-type="publisher-id">201700731</article-id>
<article-id pub-id-type="doi">10.1073/pnas.1700731114</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>PNAS Plus</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Biological Sciences</subject>
<subj-group>
<subject>Biochemistry</subject>
</subj-group>
</subj-group>
<series-title>PNAS Plus</series-title>
</article-categories>
<title-group>
<article-title>Structure of the MeCP2–TBLR1 complex reveals a molecular basis for Rett syndrome and related disorders</article-title>
<alt-title alt-title-type="short">MeCP2–TBLR1 complex and Rett syndrome</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kruusvee</surname>
<given-names>Valdeko</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="author-notes" rid="fn1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lyst</surname>
<given-names>Matthew J.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="author-notes" rid="fn1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Taylor</surname>
<given-names>Ceitidh</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tarnauskaitė</surname>
<given-names>Žygimantė</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bird</surname>
<given-names>Adrian P.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cook</surname>
<given-names>Atlanta G.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>2</sup>
</xref>
</contrib>
<aff id="aff1"><sup>a</sup>Wellcome Trust Centre for Cell Biology, <institution>University of Edinburgh</institution>, Edinburgh EH9 3BF, <country>United Kingdom</country>;</aff>
<aff id="aff2"><sup>b</sup>MRC Human Genetics Unit, MRC Institute of Genetics &amp; Molecular Medicine, <institution>University of Edinburgh</institution>, Western General Hospital, Edinburgh EH4 2XU, <country>United Kingdom</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><sup>2</sup>To whom correspondence may be addressed. Email: <email>a.bird@ed.ac.uk</email> or <email>atlanta.cook@ed.ac.uk</email>.</corresp>
<fn fn-type="edited-by">
<p>Contributed by Adrian P. Bird, March 7, 2017 (sent for review January 19, 2017; reviewed by Xiaodong Cheng and Zhaolan Zhou)</p>
</fn>
<fn fn-type="con">
<p>Author contributions: V.K., M.J.L., A.P.B., and A.G.C. designed research; V.K., M.J.L., C.T., and Ž.T. performed research; V.K., M.J.L., and A.G.C. analyzed data; and V.K., M.J.L., A.P.B., and A.G.C. wrote the paper.</p>
</fn>
<fn fn-type="con">
<p>Reviewers: X.C., Emory University School of Medicine; and Z.Z., University of Pennsylvania.</p>
</fn>
<fn fn-type="equal" id="fn1">
<p><sup>1</sup>V.K. and M.J.L. contributed equally to this work.</p>
</fn>
<fn fn-type="COI-statement">
<p>Conflict of interest statement: A.P.B. is a member of the Board of ArRETT, a company based in the United States with the goal of developing therapies for Rett syndrome.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>18</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>27</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>27</day>
<month>3</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>114</volume>
<issue>16</issue>
<fpage>E3243</fpage>
<lpage>E3250</lpage>
<permissions>
<license license-type="open-access">
<license-p>Freely available online through the PNAS open access option.</license-p>
</license>
</permissions>
<self-uri xlink:href="pnas.201700731.pdf" xlink:title="pdf"></self-uri>
<abstract abstract-type="executive-summary">
<title>Significance</title>
<p>Methyl-CpG–binding protein 2 (MeCP2) links epigenetics, brain function, and neurological disease. Mutations in the MeCP2 protein cause Rett syndrome (RTT), making it imperative to determine its mechanism of action. One domain of MeCP2 targets it to methylated DNA, but little was known about a second essential domain except that it recruits a gene-silencing complex. We determined that transducin beta-like (TBL) subunits of the silencing complex bind MeCP2 and solved the structure of the binary complex. Strikingly, amino acids mutated in RTT are precisely those amino acids that intimately contact the TBL subunits. Furthermore, mutations in TBL proteins that cause intellectual disability block interaction with MeCP2. Our data suggest that the TBL–MeCP2 interaction is essential for brain function.</p>
</abstract>
<abstract>
<p>Rett syndrome (RTT) is an X-linked neurological disorder caused by mutations in the methyl-CpG–binding protein 2 (<italic>MeCP2</italic>) gene. The majority of RTT missense mutations disrupt the interaction of the MeCP2 with DNA or the nuclear receptor corepressor (NCoR)/silencing mediator of retinoic acid and thyroid receptors (SMRT) corepressor complex. Here, we show that the “NCoR/SMRT interaction domain” (NID) of MeCP2 directly contacts transducin beta-like 1 (TBL1) and TBL1 related (TBLR1), two paralogs that are core components of NCoR/SMRT. We determine the cocrystal structure of the MeCP2 NID in complex with the WD40 domain of TBLR1 and confirm by in vitro and ex vivo assays that mutation of interacting residues of TBLR1 and TBL1 disrupts binding to MeCP2. Strikingly, the four MeCP2-NID residues mutated in RTT are those residues that make the most extensive contacts with TBLR1. Moreover, missense mutations in the gene for TBLR1 that are associated with intellectual disability also prevent MeCP2 binding. Our study therefore reveals the molecular basis of an interaction that is crucial for optimal brain function.</p>
</abstract>
<kwd-group>
<kwd>MeCP2</kwd>
<kwd>NCoR/SMRT</kwd>
<kwd>Rett syndrome</kwd>
<kwd>TBL proteins</kwd>
<kwd>intellectual disability</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">Wellcome Trust<named-content content-type="funder-id">100004440</named-content></funding-source>
<award-id rid="sp1">091580</award-id>
</award-group>
<award-group id="gs2">
<funding-source id="sp2">Wellcome Trust<named-content content-type="funder-id">100004440</named-content></funding-source>
<award-id rid="sp2">107930</award-id>
</award-group>
<award-group id="gs3">
<funding-source id="sp3">Wellcome Trust<named-content content-type="funder-id">100004440</named-content></funding-source>
<award-id rid="sp3">092076</award-id>
</award-group>
<award-group id="gs4">
<funding-source id="sp4">Wellcome Trust<named-content content-type="funder-id">100004440</named-content></funding-source>
<award-id rid="sp4">095822</award-id>
</award-group>
<award-group id="gs5">
<funding-source id="sp5">Wellcome Trust<named-content content-type="funder-id">100004440</named-content></funding-source>
<award-id rid="sp5">108504</award-id>
</award-group>
<award-group id="gs6">
<funding-source id="sp6">Medical Research Council (MRC)<named-content content-type="funder-id">501100000265</named-content></funding-source>
<award-id rid="sp6">G1000520/1</award-id>
</award-group>
<award-group id="gs7">
<funding-source id="sp7">Rett Syndrome Research Trust</funding-source>
<award-id rid="sp7">4951</award-id>
</award-group>
</funding-group>
<counts>
<page-count count="8"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>